Preparation of prolonged release clarithromycin microparticles for oral use and their in vitro evaluation

Archives of Pharmacal Research

Volumn 29, Issue 10, 2006, Pages 921-927

  Genç, Lütfi ^a   Demirel, Müzeyyen ^a   Yazan, Yasemin ^a  

^a ANADOLU UNIVERSITY   (Turkey)

Author keywords

Casting drying; Clarithromycin; Eudragit RL 100 and RS 100; Microparticle; Prolonged release; Spray drying

Indexed keywords

ACRYLIC ACID RESIN; ANTIINFECTIVE AGENT; CLARITHROMYCIN; EUDRAGIT RS; EXCIPIENT;

ARTICLE; BIOAVAILABILITY; CHEMISTRY; CRYSTALLIZATION; DELAYED RELEASE FORMULATION; DRUG STABILITY; ECONOMICS; FREEZE DRYING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFRARED SPECTROPHOTOMETRY; METHODOLOGY; ORAL DRUG ADMINISTRATION; PARTICLE SIZE; PHARMACEUTICS; REPRODUCIBILITY; SOLUBILITY; SYNTHESIS; TIME; X RAY DIFFRACTION;

ACRYLIC RESINS; ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLARITHROMYCIN; CRYSTALLIZATION; DELAYED-ACTION PREPARATIONS; DRUG STABILITY; EXCIPIENTS; FREEZE DRYING; PARTICLE SIZE; REPRODUCIBILITY OF RESULTS; SOLUBILITY; SPECTROPHOTOMETRY, INFRARED; TECHNOLOGY, PHARMACEUTICAL; TIME FACTORS; X-RAY DIFFRACTION;

EID: 33751342461     PISSN: 02536269     EISSN: 02536269     Source Type: Journal    
DOI: 10.1007/BF02973915     Document Type: Article

References (22)

1. Adam, D., Glaser-Caldow, E., Wachter, J., Brueckner, O.-J., Hein, J., Kroemer, B., and Hirsch, J., Comparative efficacy of clarithromycin modified rlelase and immediate relaese formulations in the treatment of lower respiratory tract infection. Clin. Ther., 23(4), 585-595 (2001).
2. Barradell, L. B., Plosker, G. L., and Mctavish, D., Clarithromycin: A review of its pharmacological properties and therapeutic use in Mycobacterium avium-intracellulare complex infection in patients with Acquired Immune Deficiency Syndrome. Drugs, 46(2), 289-312 (1993).
3. Bele, M., Dmitrasinovic, D., Planinsek, O., Salobir, M., Srcic, S., Gabescek, M., and Jamnik, J., Silica coating on clarithromycin. Int. J. Pharm., 291, 149-153 (2005).
4. Beuving, G., Validation of Analytical Methods. Validation Seminar, Istanbul, 31 May-01 June 2001.
5. Chu, S.-Y., Sennello, L. T., and Sonders, R. C., Simultaneous determination of clarithromycin and 14-hydroxy-clarithromycin in plasma and urine using HPLC with electronical detection. J. Chromatogr., 571, 199-208 (1991).
6. Conte, J. E., Golden, J. A., Duncan, S., Mckenna, E., and Zurlinden, E., Intra-pulmonar pharmacokinetics of clarithromycin and of erythromycin. Antimicrob. Agents Chemother., 39(2), 334-338 (1995).
7. Erah, P. O., Goddard, A. F., Barrett, D. A., Shaw, P. N., and Spillr, R. C., The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J. Antimicrob. Chemother., 39, 5-12 (1997).
8. Guay, D. R. P., Gustavson, L. E., Devcich, K. J., Zhang, J., Cao, G., and Olson, C.A., Pharmacokinetics and tolerability of extended-release clarithromycin. Clin. Ther., 23(4), 566-577 (2001).
9. Kim, S. J., Hahn, S. K., Kim, M. J., Kim, D. H., and Lee, Y. P., Development of a novel sustained release formulation of recombinant human growth hormone using sodium hyaluronate microparticles. J. Control. Release, 104, 323-335 (2005).
10. Li, Y., Zhu, K. J., Zhang, J. X., Jiang, H. L., Liu, J. H., Hao, Y. L., Yasuda, H., Ichimaru, A., and Yamamoto, K., In vitro and in vivo studies of cyclosporin A-Loaded microspheres based on copolymers of lactide and ε-Caprolactone: Comparison with Conventional PLGA Microspheres. Int. J. Pharm., 295, 67-76 (2005).
11. Louis, St., Drug Facts and Comparisons. A Wolters Kluwer Company, USA, p.2189 (1997).
12. Martin, T. M., Bandi, N., Shulz, R., Roberts, C. B., and Kompella, U. B., Preparation of budesonide and budesonide-PLA microparticles using supercritical fluid precipitation technology. AAPS PharmSci. Tech., 3(3), 1-11 (2002).
13. Morgan, D. K., Brown, D. M., Rotsch, T. D., and Plasz, A. C., A reversed-phase HPLC method for the determination and identification of clarithromycin as the drug substance and in various dosage forms. J. Pharm. Biomed. Anal., 9(3), 261-269 (1991).
14. Mu, I., Teo, M.-M., Ning, H.-Z., and Feng, S.-S., Novel powder formulations for controlled delivery of poorly soluble anticancer drug: Application and investigation of TPGS and PEC in spray-dried particulate system. J. Control. Release, 103, 565-575 (2005).
15. Nakagawa, Y., Itai, S., Yoshida, T., and Nagai, T., Physicochemical properties and stability in the acidic solution of a new macrolide antibiotic, clarithromycin, in comparison with erythromycin. Chem. Pharm. Bull., 40(3), 725-728 (1992).
16. Oneda, F. and Ré, M. I., The effect of formulation variables on the dissolution and physical properties of spray-dried microspheres containing organic salts. Powder Technol., 130, 377-384 (2003).
17. Pav, B., Misztal, G., Hopkala, H., and Drozd, J., Development and validation of a HPLC method for the determination of cetrizine in pharmaceutical dosage forms. Pharmazie, 57, 313-315 (2002).
18. Perng, C. Y., Kearney, A. S., Patel, K., Palepu, N. R., and Zuber, G., Investigation of formulation approaches to improve the dissolution of SB-210661 a poorly water soluble 5-Lipoxygenase inhibitor. Int. J. Pharm., 176, 31-38 (1998).
19. Reiley, C. M. and Fell, F., Development and validation of analytical methods. Prog. Pharm. Biomed. Anal., 3, 20-22 (1996).
20. Rotsch, T. D., Spanton, M., Cugier, P., and Plasz, A. C., Determination of clarithromycin as a conta-minant on surfaces by HPLC using electronical detection. Pharm. Res., 8(8), 989-991 (1991).
21. U. S. Pharmacopeia National Formulary, USP 26-NF 21, 3th Ed.,Mack Printing Company: Easton, U.S.A., pp. 2439-2445 (2003).
22. Yonemochi, E., Kitahara, S., Maeda, S., Yamamura, S., Oguchi, T., and Yamoto, K., Physicochemical properties of amorphous clarithromycin obtained by grinding and spray drying. Eur. J. Pharm. Sci., 7, 331-338 (1999).